AbbVie’s Strategic Acquisitions and Trial Success Fuel 0.72% Rally Despite 102nd-Ranked 920M Volume

AbbVie (ABBV) rose 0.72% on Sept. 2, 2025, with a trading volume of $920 million, ranking 102nd in market activity. The stock’s performance followed key corporate developments, including strategic acquisitions and clinical trial milestones. AbbVie announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 9, where management will engage in a fireside chat. This event is expected to highlight the company’s growth strategies amid a competitive healthcare landscape.

The firm expanded its psychiatry pipeline by acquiring Gilgamesh Pharmaceuticals’ bretisilocin, a Phase 2 psychedelic compound for major depressive disorder. This acquisition underscores AbbVie’s focus on innovative therapies in mental health. Separately, the company reported positive topline results from its second Phase 3 UP-AA trial for upadacitinib (RINVOQ®) in treating alopecia areata. The drug demonstrated significant efficacy, with 45.2% and 55.0% of patients achieving key endpoints in severe and non-severe cases, respectively.

AbbVie further bolstered its immunology portfolio through the acquisition of Capstan Therapeutics, adding a potential first-in-class anti-CD19 CAR-T therapy candidate for autoimmune diseases. Earlier in 2025, the company also completed its purchase of Nimble Therapeutics to enhance its pipeline. These moves reflect a strategic emphasis on expanding therapeutic options and strengthening long-term revenue streams.

Backtesting analysis indicates that AbbVie’s stock has shown a 90-day return of 8.5% and a 365-day return of 22.3%. The 3-year projected return is estimated at 15.6%, factoring in current pipeline progress and market positioning.